**Thesis:** Peptides are a programmable middle layer between small molecules and biologics, and the history of the field is the history of paying down the *peptide tax* — proteolysis, rapid clearance, membrane impermeability, and weak oral exposure — with medicinal chemistry, formulation, and delivery engineering. # Intro — The Programmable Middle Layer - Frame peptides as a recognition layer sitting between small molecules and biologics, and state the three-axis thesis: target geometry × PK engineering × manufacturability. - Major peptide advantages - Low toxicity - they just decompose into amino acids. Also fewer off-target effects due to high selectivity - High selectivity - they are larger than small molecules and therefore can be custom-designed against a larger portion of the target (hard for an off-target protein to match a 15-residue interface by accident) - Potency - can exhibit very strong binding to their target, again due to the large interface they can bind to on the target (more contacts == more binding strength) - Ability to target large, shallow binding surfaces - small molecules are generally limited to deep, hydrophobic pockets. Peptides can target large, flat binding surfaces (such as protein-protein interactions) - Use in human pathways - many natural human pathways use peptides (e.g., GLP-1). Makes peptides a natural therapeutic modality to mimic naturally occurring human molecules - Major peptide disadvantages - Low oral bioavailability - Difficult to enter cells - Very short half-life - More expensive to produce, harder to transport, and harder to administer than small molecules # From Hormone Analogs to a Modality - Why peptides spent decades boxed in as endocrine analogs, and how the peptide tax (proteolysis, clearance, impermeability, oral exposure) defined the reachable target space — with biologics as the first comparator anchor. # Paying Down the Peptide Tax - The medicinal chemistry moves that made modern peptide PK practical — backbone modification, D-amino acids, cyclization, PEGylation, fatty-acid derivatization, and permeation enhancers — each buying back stability, half-life, or oral exposure. # When Peptides Win — A Three-Axis Framework - A framework for modality choice along target geometry, PK engineering, and manufacturability, with RNA/oligo medicines as the foil for the geometry and delivery axes. # The GLP-1 Proof - Incretin-based therapies as the commercial proof that peptides can be mass-market drugs, cashing in directly on the fatty-acid derivatization and oral-delivery engineering from the previous sections. # Expanding the Target Surface — Cyclic Peptides and Conjugates - Whether constrained cyclic peptides, macrocycles, and peptide-drug conjugates represent a genuine expansion of addressable target space (PPIs, intracellular access, tumour penetration) versus a parallel improvement track, with ADCs as the PDC foil. # Manufacturing is the Other Bottleneck - Why synthesis is load-bearing for the thesis: SPPS aggregation, sequence-dependent failures, and the shift toward enzymatic and ligase routes as a supply-side constraint on which peptides can actually be made at scale. # The Orforglipron Tension - The Foundayo (orforglipron) approval on Apr 1, 2026 as the closing tension: peptides may be the modality that first turns hard biology into a druggable market, but once the biology is validated, small molecules can come after the same axis with a different convenience and cost profile. # References